Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia.

We describe a modified RIA using a rabbit polyclonal antiserum directed against the first 21 amino acids of the E-domain (E-21) of proinsulin-like growth factor-II (pro-IGF-II). For standardization, we purified big IGF-II from patients with nonislet cell tumor hypoglycemia (NICTH). Under the conditions of our assay there was no significant interference from IGF-binding proteins. The big IGF-II present in the serum of a patient with NICTH displaced [125I]E-(1-21) from antibody parallel to our big IGF-II standard. We found a progressive rise in E-21 immunoactivity (IA) during childhood, with somewhat higher values in girls than in boys. In normal adults the mean E-21 IA level was 138 +/- 49 (+/- SD) micrograms/L. Women with twin pregnancies had higher E-21 IA than women with single pregnancies (302 +/- 66 compared with 120 +/- 18 micrograms/L). We found a marked elevation of E-21 IA in patients with NICTH due to sarcomas (n = 3), hepatoma (n = 2), adrenal carcinoma (n = 1), and carcinoma of the lung (n = 1). No elevation of E-21 IA was present in the serum of a hypoglycemic patient with a hypernephroma or another patient with carcinoma of the lung. Marked elevation of E-21 IA was observed in the serum of patients with renal failure receiving chronic hemodialysis. We conclude that this assay will prove useful in the diagnosis of NICTH in patients who are not azotemic and the investigation of the role of the kidney in clearing products of pro-IGF-II processing.

[1]  W. Daughaday,et al.  Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum. , 1992, Journal of Clinical Endocrinology and Metabolism.

[2]  R. Baxter,et al.  Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. , 1991, The Journal of clinical endocrinology and metabolism.

[3]  W. Lee,et al.  Measurement of insulin-like growth factor-II in physiological fluids and tissues. II. Extraction quantification in rat tissues. , 1991, Endocrinology.

[4]  W. Lee,et al.  Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids. , 1991, Endocrinology.

[5]  W. R. Hudgins,et al.  Development of a specific radioimmuno assay for E domain containing forms of insulin-like growth factor II. , 1991, Advances in experimental medicine and biology.

[6]  W. Daughaday,et al.  Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals. , 1990, The Journal of laboratory and clinical medicine.

[7]  M. Israel,et al.  Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. , 1989, The Journal of clinical investigation.

[8]  W. Daughaday,et al.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Roholl,et al.  Expression of insulin‐like growth factor‐I and ‐II genes in human smooth muscle tumours. , 1988, The EMBO journal.

[10]  D. Hill,et al.  Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. , 1987, Endocrinology.

[11]  J. Irminger,et al.  Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Daughaday [24] Radioligand assays for insulin-like growth factor II , 1987 .

[13]  T. Merimee,et al.  Insulin-like growth factors in patients with nonislet cell tumors and hypoglycemia. , 1986, Metabolism: clinical and experimental.

[14]  J. Scott,et al.  Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues , 1985, Nature.

[15]  M. Eccles,et al.  Expression of insulin-like growth factor-II transcripts in Wilms' tumour , 1985, Nature.

[16]  P. Zumstein,et al.  Amino acid sequence of a variant pro-form of insulin-like growth factor II. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Svoboda,et al.  [61] Purification of somatomedin-C/insulin-like growth factor I , 1985 .

[18]  R. Humbel,et al.  Evidence for two species of insulin-like growth factor II (IGF II and "big" IGF II) in human spinal fluid. , 1982, Endocrinology.

[19]  W. Daughaday,et al.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. , 1980, The Journal of clinical endocrinology and metabolism.